The FDA’s accelerated approval pathway allows cancer drugs to reach patients sooner, often based on early trial results rather than proven survival benefit.
Dr. Huseyin Naci discusses findings from a recent BMJ Medicine study examining survival gains and Medicare spending associated with these approvals. Join us to explore what faster approval means for patients, evidence standards, and health care costs.